Begin typing your search...

    India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

    India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

    India scaling up production of APIs: NITI Aayog CEO Amitabh Kant
    X
    NITI Aayog CEO Amitabh Kant

    New Delhi

    Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

    He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

    The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

    Visit news.dtnext.in to explore our interactive epaper!

    Download the DT Next app for more exciting features!

    Click here for iOS

    Click here for Android

    migrator
    Next Story